Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhujing Pill
- Development stage
- Preclinical
- Lead developer
- Chengdu University of Traditional Chinese Medicine
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Zhujing Pill is a traditional Chinese medicine (TCM) formula widely utilized for treating various ocular conditions, including diabetic retinopathy, macular degeneration (such as high myopia macular degeneration and age-related macular degeneration), and retinitis pigmentosa. Its therapeutic efficacy is attributed to a multi-component, multi-target, and multi-pathway mechanism. Key actions include anti-angiogenic effects, mediated by targeting the VEGF signaling pathway and Protein kinase C alpha (PKC-α), as well as anti-inflammatory properties through the reduction of cytokines like Interleukin-6 (IL-6) and Tumor necrosis factor (TNF). The pill also exhibits antioxidant effects by activating pathways such as Nrf2, leading to the upregulation of Heme oxygenase 1 (HO-1), and increasing levels of Superoxide Dismutase (SOD) and Glutathione Peroxidase (GSH-Px). Additionally, it is involved in regulating retinal pigment epithelium (RPE) cholesterol metabolism and modulating gut microbiota, and influences the expression of LPCAT1, CHRNA7, and NOS2 in the context of myopia progression.
- Other names
- Preserve Vistas PillZhu Jing Wan
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)CHRNA7 (α7 nicotinic receptor)MAPK3 (Mitogen-activated protein kinase 1)HIF1A (Hypoxia-inducible factor 1-alpha)HMOX1 (Heme oxygenase 1)NOS2 (Nitric Oxide Synthase 2)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)PRKCA (Protein kinase C alpha)VEGFA (Vascular endothelial growth factor A)AR (Adrenergic receptors)GPX4 (Glutathione peroxidase 4)GSK3 (Glycogen synthase kinase 3 beta)ICAM1 (Intercellular Adhesion Molecule 1)IL1B (Interleukin-1 beta)IL-6 (Interleukin 6)JUN (Transcription factor Jun)LPCAT1 (Lysophosphatidylcholine acyltransferase 1)Misfolded SOD1TP53 (Cellular Tumor Antigen p53 R175H)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on Zhujing Pill.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhujing Pill.